Linked Life Data

16207152

Source:http://linkedlifedata.com/resource/pubmed/id/16207152

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16207152rdf:typepubmed:Citationlld:pubmed
pubmed-article:16207152lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:16207152lifeskim:mentionsumls-concept:C1709519lld:lifeskim
pubmed-article:16207152lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:16207152pubmed:issue7lld:pubmed
pubmed-article:16207152pubmed:dateCreated2005-10-6lld:pubmed
pubmed-article:16207152pubmed:abstractTextExperimental evidence and observations in humans strongly support an interactive role of mutated alpha-adducin, sodium (Na(+))/potassium (K(+))-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na(+) homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomized to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover experiment with balanced randomization. Treatment will be initiated with the active drug and continued with placebo or vice versa. Each double-blind period will last 5 weeks. The primary end point is the reduction in systolic blood pressure defined as the average of three clinic readings with the patient in the sitting position. Secondary end points include the reduction in diastolic blood pressure on clinic measurement, the decrease in the 24-h blood pressure, and the incidence of end points related to safety. Secondary objectives are to investigate the dependence of the blood pressure-lowering activity on the plasma concentration of endogenous ouabain and the genetic variation of the enzymes involved in the metabolism of this hormone, and the adducin cytoskeleton proteins. Eligible patients will have Grade I or II systolic hypertension without associated conditions and no more than two additional risk factors. In conclusion, OASIS-HT is a combination of five concurrent crossover studies, one for each dose of rostafuroxin to be studied. To our knowledge, OASIS-HT is the first Phase II dose-finding study in which a genetic hypothesis is driving primary and secondary end points.lld:pubmed
pubmed-article:16207152pubmed:languageenglld:pubmed
pubmed-article:16207152pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16207152pubmed:citationSubsetIMlld:pubmed
pubmed-article:16207152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16207152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16207152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16207152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16207152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16207152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16207152pubmed:statusMEDLINElld:pubmed
pubmed-article:16207152pubmed:monthOctlld:pubmed
pubmed-article:16207152pubmed:issn1462-2416lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:FournierAlber...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:StaessenJan...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:ThijsLutgarde...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:BurnierMichel...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:BianchiGiusep...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:KuznetsovaTat...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:Kawecka-Jaszc...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:ManuntaPaoloPlld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:RedónJosepJlld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:FilipovskýJan...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:BrandEvaElld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:NikitinYuriYlld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:O'BrienEoin...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:ValentiniGiov...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:CitterioLoren...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:FerrariPatriz...lld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:CelisHildeHlld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:AccetoRokRlld:pubmed
pubmed-article:16207152pubmed:authorpubmed-author:BacchieriAnto...lld:pubmed
pubmed-article:16207152pubmed:issnTypePrintlld:pubmed
pubmed-article:16207152pubmed:volume6lld:pubmed
pubmed-article:16207152pubmed:ownerNLMlld:pubmed
pubmed-article:16207152pubmed:authorsCompleteYlld:pubmed
pubmed-article:16207152pubmed:pagination755-75lld:pubmed
pubmed-article:16207152pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:meshHeadingpubmed-meshheading:16207152...lld:pubmed
pubmed-article:16207152pubmed:year2005lld:pubmed
pubmed-article:16207152pubmed:articleTitleOASIS-HT: design of a pharmacogenomic dose-finding study.lld:pubmed
pubmed-article:16207152pubmed:affiliationDepartment of Molecular and Cardiovascular Research, Hypertension and Cardiovascular Rehabilitation Unit, Study Coordinating Centre, University of Leuven, Belgium.lld:pubmed
pubmed-article:16207152pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16207152pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16207152pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:16207152pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16207152pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16207152pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16207152lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16207152lld:pubmed